南京地区33家医院2010—2012年分子靶向抗肿瘤药利用分析  

Utilization of Molecular Targeted Anti-tumor Drugs in 33 Hospitals of Nanjing City from 2010 to 2012

作　　者：李想[1] 戴惠珍 陶琳[3] 孟玲[1] 

机构地区：[1]南京医科大学第一附属医院,南京210029 [2]江苏省医药情报研究所,南京210029 [3]上海市食品药品监督管理局科技情报研究所,上海200233

出　　处：《中国医院用药评价与分析》2014年第7期606-609,共4页Evaluation and Analysis of Drug-use in Hospitals of China

基　　金：江苏高校优势学科建设工程资助项目(NoJX10231801)

摘　　要：目的:评价南京地区医院分子靶向抗肿瘤药的利用情况。方法:采用销售金额和用药频度(DDDs)分析及排序法,对南京地区33家医院2010—2012年分子靶向抗肿瘤药的利用情况进行分析。结果:该地区医院分子靶向抗肿瘤药的销售金额和DDDs逐年增加,年均增长率分别为35.39%和18.56%。3年总销售金额排名靠前的是利妥昔单抗、重组人血管内皮抑制素、曲妥珠单抗和吉非替尼,而3年总DDDs排名靠前的是吉非替尼、重组人血管内皮抑制素和厄洛替尼。各年度销售金额排前3位的制药企业均为罗氏制药有限公司、山东先声麦得津生物制药有限公司和阿斯利康贸易有限公司。结论:2010—2012年南京地区分子靶向抗肿瘤药应用呈上升趋势,分子靶向药物越来越得到临床认可。OBJECTIVE： To evaluate the clinical utilization of molecular targeted anti-tumor drugs in Nanjing city. METH- ODS： The utilization of molecular targeted anti-tumor drugs in 33 hospitals of Nanjing city during 2010-2012 period was analyzed statistically with regard to consumption sum and DDDs. RESULTS： The consumption sum and DDDs of molecular targeted drugs in Nanjing city increased year by year, with annual growth rate of 35.39% and 18.56%, respectively. From 2010 to 2012, the top four drugs in consumption sum were rituximab, recombinant human endostatin, trastuzumab and gefitinib; the top three drugs in DDDs were gefitinib, recombinant human endostatin and erlotinib; the top three manufacturers ranked by sales amount were Roche Pharmaceuticals Co. Ltd., Shandong Simcere-Medgenn Bio-pharmaceutical Co. Ltd. and Astrazeneca Trading Co. Ltd. CONCLU- SIONS： The consumption of molecular targeted anti-tumor drugs in Nanjing city shows an upward trend from 2010 to 2012, indi- cating the increasing popularity of molecular targeted drugs.

关 键 词：分子靶向药物 抗肿瘤药 用药频度 南京地区 

分 类 号：R286[医药卫生—中药学] R969.3[医药卫生—中医学]